A Novel LC System Embeds Analytes in Pre-formed Gradients for Rapid, Ultra-Robust Proteomics

Authors
Nicolai Bache, Philipp E. Geyer, Dorte B. Bekker-Jensen, Ole Hoerning, Lasse Falkenby, Peter V. Treit, Sophia Doll, Igor Paron, Johannes B. Müller, Florian Meier, Jesper V. Olsen, Ole Vorm, and Matthias Mann

Correspondence
mmann@biochem.mpg.de

In Brief
Because of low throughput and limited robustness, nano-scale liquid chromatography has been a bottleneck for advancing proteomics in biomedical research. Here, we developed and evaluated two new LC concepts—“pre-formed gradients” and “offset gradients for peptide re-focusing”—that are both implemented in the Evosep One instrument. We evaluated robustness with more than 2000 HeLa runs, demonstrated absence of cross-contamination with crude plasma samples, high proteome coverage by fractionated HeLa and routinely measuring more than 5000 proteins/sample in just 21 minutes.

Highlights
- Pre-formed and offset gradients for high throughput, robustness and peptide re-focusing.
- Minimal cross-contamination by disposable trap columns and partial elution.
- Single shot DIA measurements achieve >5000 proteins in 21 min.
A Novel LC System Embeds Analytes in Pre-formed Gradients for Rapid, Ultra-robust Proteomics*□

Nicolai Bache‡, Philipp E. Geyer§¶, Dorte B. Bekker-Jensen¶, Ole Hoerning‡, Lasse Falkenby‡, Peter V. Treit§, Sophia Doll§, Igor Paron§, Johannes B. Müller§, Florian Meier§, Jesper V. Olsen¶, Ole Vorm‡, and Matthias Mann§¶**

To further integrate mass spectrometry (MS)-based proteomics into biomedical research and especially into clinical settings, high throughput and robustness are essential requirements. They are largely met in high-flow rate chromatographic systems for small molecules but these are not sufficiently sensitive for proteomics applications. Here we describe a new concept that delivers on these requirements while maintaining the sensitivity of current nano-flow LC systems. Low-pressure pumps elute the sample from a disposable trap column, simultaneously forming a chromatographic gradient that is stored in a long storage loop. An auxiliary gradient creates an offset, ensuring the re-focusing of the peptides before the separation on the analytical column by a single high-pressure pump. This simplified design enables robust operation over thousands of sample injections. Furthermore, the steps between injections are performed in parallel, reducing overhead time to a few minutes and allowing analysis of more than 200 samples per day. From fractionated HeLa cell lysates, deep proteomes covering more than 130,000 sequence unique peptides and close to 10,000 proteins were rapidly acquired. Using this data as a library, we demonstrate quantitation of 5200 proteins in only 21 min. Thus, the new system - termed Evosep One - analyzes samples in an extremely robust and high throughput manner, without sacrificing in depth proteomics coverage. Molecular & Cellular Proteomics 17: 10.1074/mcp.TIR118.000853, 2284–2296, 2018.

Bottom-up proteomics is a highly successful and generic technology, which now allows the analysis of complex samples ranging from bacteria through cell line systems and even human tissue samples (1). State-of-the-art workflows begin with a robust sample preparation to digest proteins and harvest purified peptides (2), which are separated by a liquid chromatography (LC) system before they are analyzed by a mass spectrometer (MS). Established software solutions automatically interpret the acquired spectra, generating lists of thousands of quantified proteins (3–8).

The current performance level is a result of improvements not only in the mass spectrometric components but also the chromatographic part of the LC-MS workflow. In the quest for ever increasing chromatographic separation power, columns have become longer and particle sizes smaller - now reaching the sub 2 μm range. This may require pump pressures more than 1000 bar, presenting great engineering challenges for both the pumps and the entire LC system, often limiting robustness in routine operation. Thus, chromatography remains a weak link in MS-based proteomics workflows, leading to calls for new approaches (9). Furthermore, irreproducibility of retention times within and between laboratories severely limits strategies that rely on the transfer of accurate retention times, especially targeted proteomics (10), data independent acquisition (11) and “match between runs” at the MS level (12, 13).

There is great interest in applying the increasing power of MS-based proteomics to diagnostic and clinical questions (14). “Clinical proteomics”, however, requires far more stability and reproducibility than that available even in the most advanced MS-based proteomics laboratories. Note that irreproducibility and robustness issues are not features of LC-MS per se, as the measurement of small molecules is firmly established in clinical laboratories around the world, which routinely measure hundreds of samples per day. The two key differences of these LC systems to the one applied in proteomics are their much larger column diameters (20-fold) and flow rates (1000-fold), making them much easier to control and less error-prone. Increasing the flow rates to achieve greater robustness has already been advocated in the context

From the ‡Evosep Biosystems, Odense, Denmark; §Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany; ¶Novo Nordisk Foundation Center for Protein Research, Proteomics Program, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

© 2018 Bache et al. Published by The American Society for Biochemistry and Molecular Biology, Inc.

Molecular & Cellular Proteomics 17.11

2285
of cancer proteomics (15). However, the signal intensity in electrospray ionization is concentration dependent and reducing sensitivity at higher flow rates, which limits these approaches to a few \( \mu \text{L/min} \). Apart from high robustness, throughput is the other central requirement for MS-based proteomics, if it is to enter routine clinical use. Instead, current proteomics workflows generally employ fractionation—multiplying measurement time—or use relatively long gradient times.

In a recent large-scale plasma proteomics study measured in our laboratory, involving more than a thousand samples, 80% of the overall down time was attributable to the HPLC system rather than the MS. At the same time, column equilibration, loading and washing steps between runs limited the attractiveness of very short gradients (16, 17).

Several years ago, some of the current authors devised a different sample loading and injection approach. Termed speLC, for solid-phase-extraction (nano) liquid chromatography, it was intended for very high sample throughput needed for clinical application (18). The speLC made use of the same StageTips that are commonly employed in proteomics for micro-scale purification of peptides and crude manual fractionation (19–21). Instead of eluting into the autosampler vial of the HPLC system, a low-pressure pump passed a 5–10 min gradient through the StageTip itself and directly toward the MS. The speLC system can analyze 192 \( E. \text{coli} \) samples in only 30 h, as well as identifying more than 500 proteins from a HeLa cell lysate in less than 10 min (18). In subsequent work, speLC was combined with pre-fractionation such as 1D gel electrophoresis or strong cation exchange (SCX), capitalizing on its ability to analyze each of the fractions in 10 min or less (22). Although useful for simple protein mixtures, the low-pressure elution from StageTips and use of only very short analytical columns inherently limited chromatographic separation power of this system.

In the work reported here, we aimed to preserve the benefits of the original speLC device while also achieving the desirable features of modern HPLC instruments. We realized this goal by coupling elution through the StageTips to a novel downstream workflow. In the Evosep One design, peptides are eluted at low pressure and flow rates of tens of \( \mu \text{L/min} \) from a special StageTip - termed Evotip™. Notably, the gradient along with the eluted analytes are captured in a long capillary loop. A single high-pressure pump then applies the stored gradient to an analytical nano-scale column. This results in undiminished chromatographic separation performance while eliminating the need to form a gradient at high pressure. Thus, this layout marries the convenience and robustness of large columns, high-flow systems with the sensitivity of narrow column diameters and low-flow rates of nano-LC systems. We further detail the principle of operation and development of the Evosep instrument in detail and investigate its robustness, throughput, and reproducibility in typical applications encountered in MS-based proteomics.

**EXPERIMENTAL PROCEDURES**

*Description of the Liquid Chromatography System—The Evosep One incorporates four low-pressure single stroke piston pumps (A, B, C, and D) and one high-pressure single stroke piston pump (HP) (Fig. 1A; supplemental Fig. S1A, S1B). Together they create a separate low- and high-pressure sub-system. Each pump is equipped with a pressure and flow sensor to monitor and precisely control the flow of the individual solvent. A custom 12-port valve (operating at low-pressure) diverts the flow of the low-pressure pumps either toward the solvent bottles (sol A, sol B) for refilling or toward the system for analysis. The high-pressure pump has a separate 6-port valve (operating at high-pressure) for refilling.*

The only common flow path is a storage loop, which is either connected to the low- or high-pressure sub-system and is controlled by a 6-port rotary valve (Fig. 1A). In this way, the high-pressure sub-system is always connected to the analytical or separation column but is either in-line or bypasses the storage loop. In contrast, the low-pressure sub-system is always connected to waste but either in-line or bypassing the storage loop. Thus, the storage loop becomes the bridge between the low- and high-pressure sub-systems.

The separate steps are illustrated in the timetable and in the flow path diagrams, highlighting the individual stages of an LC-MS run (Fig. 1B; supplemental Fig. S2–S9). At the beginning of a new LC-MS run, the XYZ-axis manipulator of the Evosep One picks up an individual disposable trap column (Evotip) with its ceramic needle and positions it in-line with the solvent flow path at the A/B/C/D mixing cross (Fig. 1A; supplemental Fig. S1A, S1B).

In the second step, pumps A and B then form a primary gradient at the A/B mixing tee that flows through the disposable trap column, eluting the analytes of interest (Fig. 1B; supplemental Fig. S2). The organic content of this initial gradient is limited to less than 35% to ensure that only peptides of interest are eluted off the tips while unwanted compounds such as polymers, lipids, and other highly hydrophobic compounds remain bound to the single-use, disposable tips along with any particulate matter from the loaded samples. Furthermore, the final elution volume of this initial gradient is limited to few \( \mu \text{L} \) to ensure very precise elution and minimize bleeding of the more hydrophobic molecules. This “partial elution” concept will be further described in RESULTS AND DISCUSSION.

The two additional low-pressure pumps, C and D then modify the eluent at the mixing cross A/B/C/D to create an “offset” to the initial gradient (supplemental Fig. S2). This has the purpose of lowering the organic contents, such that the analytes are initially retained on the analytical column. The offset gradient with the embedded analytes is moved into the storage loop before being switched in-line with the high-pressure pump. In parallel to the first two steps, the high-pressure pump is filled (supplemental Fig. S3) and the analytical column is equilibrated (supplemental Fig. S4). Subsequently, the Evosep One switches the storage loop in-line with the high-pressure pump and the preformed gradient with the embedded analytes is pushed toward the analytical column for high performance separation (supplemental Fig. S5). In parallel to the LC-MS run, the Evosep One is prepared for the next sample by ejecting the disposable trap column, washing the mixing cross A/B/C/D and the ceramic needle, refilling the low-pressure pumps and aligning the solvent flows of the low-pressure pumps (Fig. 1B; supplemental Fig. S6–S9).

The instrument contains procedures to monitor its state during an LC run and can detect high pressure in different parts of the system, warn of potential leaks or the lack of an Evotips in the designated autosampler position. It also has built in trouble shooting procedures.
through the Chronos software user interface. Moreover, the Evosep One carries out preparatory actions before a sample run.

**Cell Culture**—HeLa cells were cultured in high glucose DMEM with 10% fetal bovine serum and 1% penicillin-streptomycin (Life Technologies, Inc.). Cells were counted using an Invitrogen countess cell counter and stored after snap freezing at −80 °C.

**Tryptophan Fluorescence Emission Assay for Protein Quantification**—Protein concentrations were determined in 8 M urea by tryptophan fluorescence emission at 350 nm, using an excitation wavelength of 295 nm. Tryptophan at a concentration of 0.1 mg/ml in 8 M urea was used to establish a standard calibration curve (0–4 μl). We estimated that 0.1 μg/μl tryptophan are equivalent to the emission of 7 μg/μl of human protein extract, if tryptophan on average accounts for 1.3% of human protein amino acid composition.

**Protein Digestion**—For sample preparation we used the iST kit for proteomic samples (2), starting with 10⁶ HeLa cells according to the manufacturer’s instructions (P.O. 00001, PreOmics GmbH).

**Robustness Optimization**—To test and optimize robustness, we injected and analyzed over 2000 times tryptic peptides of HeLa cells, initially in exploratory batches. For this experiment, we used the breadboard model of the Evosep One coupled to a LTQ Orbitrap instrument. All issues were protocolled, and the system was optimized during the test and in the exploratory phase, the instrument was only stopped for the optimization of hardware and software components. The last 1500 HeLa samples were analyzed on a single column to analyze variation in the system and the wear of the column.

**Plasma Proteomics**—Blood was taken by venipuncture using a commercially available winged infusion set and collection tubes containing EDTA and centrifuged for 15 min at 2000 × g to harvest plasma. Blood was sampled from a healthy donor, who provided written informed consent, with prior approval of the ethics committee of the Max Planck Society. The plasma was distributed into a 96-well plate and subsequently processed with an automated sam-

---

**Fig. 1. Evosep One flow diagram and time schedule.** A, Almost all of the system runs at low pressure (10–20 bar), increasing the lifetime and robustness of the LC. Only a single pump and flow path operates at high pressure and this does not involve any solvent mixing. B, Stepwise timetable including all steps that the Evosep One is performing during a LC-MS run for the 60 samples/day method. The activities for the autosampler, the low-pressure pumps and the high-pressure pump are color-coded in green, yellow and blue, respectively. For a detailed flow diagram with highlighted flow path states see supplemental Fig. S2–S9.
Pre-processed gradient liquid chromatography was used for plasma proteome profiling as described previously [16].

**High Throughput of Low Complexity Samples**—the “UP51 Proteomic Standard” (Sigma-Aldrich) was digested as indicated above using the PreOmics IST kit and the peptides were analyzed with the 200 samples/day method (5.6 min gradient) with a 2 μl/min flow on a 5 cm C18 column (3 μm particle size).

**Fractionation**—Peptides for deep proteome analysis were fractionated using a reversed-phase Acquity CSH C18 1.7 μm 1 × 150 mm column (Waters, Milford, MA) on an Ultimate 3000 high-pressure liquid chromatography (HPLC) system ( Dionex, Sunnyvale, CA) operating at 30 μl/min. Buffer A (5 mM ammonium bicarbonate) and buffer B (100% ACN) were used. Peptides were separated by a linear gradient from 5% B to 35% B in 55 min, followed by a linear increase to 70% B in 8 min. In total, 46 fractions were collected without concatenation. For nano-flow LC-MS/MS, the loading amount was kept constant at 500 ng per injection for the Easy-nLC 1200, while 500 ng from each fraction was loaded on an Evice.

**UV Gradient Storage Experiment**—To assess the effect of diffusion as a function of storage time in a storage loop, we built a test rig to mimic Evoice One operation as illustrated in figure 2. A set of Zirconium nano pumps (Prolab Instruments, GmbH, Switzerland, pump A: 0.1% formic acid (FA) in H2O, Pump B: 0.1% FA, 1% acetonitrile in acetonitrile) were programed to create the following composition profile: 0–5 min 5% B, 5–10 min 5–95% B, 10–13 min 95% B, 13–15 min 95–5%, 15–18 min 5%, 18–23 min 5–95% B, 23–25 min 95% B, 25–27 min 95–5% B, 27–30 min 5% B. This was delivered into a coiled (diameter 10 cm) fused silica storage loop (length 7 m, i.d. 100 μm, OD375, Polymicro Technologies). After a specified storage time had passed, a third Zirconium pump pushed the content out of the loop at a flow rate of 2 μl/min toward a UV detector (SpectraFlow 501, SunChrom) equipped with a nano-flow cell (5 nl) set to record the absorption at 265 nm. The storage loop and the three pumps were all connected to a standard 6-port Vici valve (Valco Instruments Co. Inc.) to control the flow path using a script.

**Evaluation of Chromatographic Performance**—We loaded 250 ng of a commercial HeLa digest (Pierce, no. 1868284) spiked in with 100 fmol of PicoSure Test Standard (eight synthetic peptide mix, New Objective PS-STDN) and loaded the mix on Evice tips. For each of the five gradient methods, four replicates were analyzed using a Thermo Q Exactive Exactset to acquire full range scans (resolution 35k) and targeted MS2 (resolution 17.5k) of the eight synthetic peptides in a scheduled table (Fig. 6B). Skyline was used to extract between 4 and 6 MS2 ions (parallel reaction monitoring) for each of the 8 peptides. Chromatographic profiles were exported from Skyline and peak characteristics for each peak was extracted using a script.

**Loading of Evotips**—Tips were activated with consecutive 100 μl wash steps of 100% ACN, 50% ACN in 0.5% formic acid in H2O followed by two times 0.5% formic acid in H2O. BSA or HeLa peptides were loaded in 0.5% formic acid in H2O. The tip activation protocol was later optimized to use 1-propanol for wetting the C18 material prior to equilibration.

**High-pressure Liquid Chromatography and Mass Spectrometry**—LC-MS instrumentation consisted of a breadboard Evoice One coupled to an LTO Orbitrap for the more than 2000 HeLa injection experiment, and the Evoice One production version coupled to a Q Exactive HF-X Orbitrap (Thermo Fisher Scientific) for all other experiments. Purified peptides were separated on the HPLC columns with 3 μm Reprosil-Pur C18 beads (Dr. Maisch, Ammerbuch, Germany) and dimensions indicated below in Fig. 6B. On the LTO Orbitrap MS, data were acquired with a Top6 data dependent shotgun method and with a Top12 method for the Q Exactive HF-X instrument. On the Q Exactive HF-X Orbitrap, the target value for the full scan MS spectra was 3 × 10^6 charges in the 300–1650 m/z range with a maximum injection time of 50 ms and a resolution of 60,000 at m/z 200. Fragmentation of precursor ions was performed by higher-energy C-trap dissociation (HCD) with a normalized collision energy of 27 eV (24). MS/MS scans were performed at a resolution of 15,000 at m/z 200 with an ion target value of 5 × 10^4 and a maximum injection time of 25 ms. Dynamic exclusion was set to 15 s to avoid repeated sequencing of identical peptides.

**Deep Proteome and Dia Experiments**—HeLa cells were harvested at ~80% confluence by washing twice with PBS and subsequently adding boiling lysis buffer (6 M guanidinium hydrochloride (GdnCl), 5 mM tris(2-carboxyethyl)phosphine, 10 mM chloroacetamide, 100 mM Tris pH 8.5) directly to the plate. The cell lysate was collected by scraping the plate and boiled for an additional 10 min, followed by micro tip probe sonication (Vibra-Cell VCX130, Sonics, Newton, CT) for 2 min with pulses of 1 s on and 1 s off at 80% amplitude. Protein concentration was estimated by Bradford assay, and the lysate was digested with LysC (Wako) in an enzyme/protein ratio of 1:100 (w/w) for 1 h, followed by dilution with 25 mM Tris, pH 8.5, to 2 M GdnCl and further digested overnight with trypsin (1:100 w/w). Protease activity was quenched by acidification with trifluoroacetic acid (TFA) to a final concentration of ~1%, and the resulting peptide mixture was concentrated on Sep-Pak (C18 Classic Cartridge, Waters, Milford, MA). Elution was done with 2 ml of 40% acetonitrile (ACN), followed by 2 ml of 60% ACN. The eluates were combined and volume reduced by SpeedVac (Eppendorf, Germany), and the final peptide concentration was estimated by measuring absorbance at 280 nm on a NanoDrop spectrophotometer (NanoDrop 2000C, Thermo Fisher Scientific, Germany). For Dia samples, IRT peptides (Biognosys AB, Schlieren, Switzerland) were added prior to MS analysis according to the manufacturer’s protocol. For samples analyzed on the Evosep One, an in-house packed 12 cm, 150 μm i.d. capillary column with 1.9 μm Reprosil-Pur C18 beads (Dr. Maisch, Ammerbuch, Germany) was used, while samples analyzed on the Easy-nLC 1200 were separated in an in-house packed 15 cm, 75 μm i.d. capillary column with the specifications as described above. The column temperature was maintained at 40 °C using an integrated column oven (PRSO-V1, Sonation, Biberach, Germany) and interfaced online with the mass spectrometer.

**Data Analysis**—MS raw files were analyzed by the MaxQuant software (version 1.5.6.8) (3) and fragments lists were searched against the human Uniprot Reference Proteome without isoforms (April 2017 release with 21,042 protein sequences) by the Andromeda search engine (25) with tryptic carbamidomethylation as a fixed modification and N-terminal acetylation and methionine oxidations as variable modifications. The experiment for the 200 samples/day method was analyzed with the UPS1 FASTA file, downloaded from the homepage of Sigma-Aldrich (April 2018). We set the false discovery rate (FDR) to 0.01 at the peptide and protein levels and specified a minimum length of 7 amino acids for peptides. Enzyme specificity was set as C-terminal to arginine and lysine as expected using trypsin and LysC as proteases, and a maximum of two missed cleavages. An initial precursor mass deviation up to 7 ppm and a fragment mass deviation of 20 ppm were specified.

Data independent analysis (DIA) results were processed with Spectronaut version 11.0.15038.19.19667, using default settings (Biognosys, Zurich, Switzerland). A project specific spectral library was imported from the separate MaxQuant analysis of the combined analysis of the 46 pre-fractionated HeLa fractions, and Dia files were analyzed using default settings. Information about precursors, peptides and proteins identified by the Spectronaut software are available in Supplemental Table S1 and S2.

All bioinformatics analyses were done with the Perseus software (26) of the MaxQuant computational platform.
RESULTS AND DISCUSSION

Principle of Analyte Embedding in Pre-formed Gradients—

Our key idea in making nano-LC as robust as high-flow LC was to decouple gradient formation from the high resolution, high-pressure separation on an analytical column. As in established peptide purification strategies, the peptides are first loaded on Evotips (a form of solid phase extraction tips like StageTips (20)). However, instead of eluting the peptides from the tips, drying them to remove the organic content and re-suspending them in injection buffer, we directly elute from the Evotip into the capillary loop. This is accomplished at pressures of only a few bar by two syringe pumps A and B at flow rates of 10 to 20 μl/min (Fig. 1). Note that an entire gradient can be stored in a several meters long fused silica capillary - already containing the individual peptides at the organic content where they elute from the C18 material. For instance, a 4 m long capillary of 100 μm inner diameter (i.d.) has a volume of 31.5 μl, enough for a subsequent analytical column separation of 31.5 min at 1 μl/min or 90 min at 350 nl/min.

We first asked if the gradient would be affected over time in the storage loop due to diffusion (27). Considering the very high aspect ratio of column length compared with i.d. (40,000 in the example above), this appears to be unlikely. Further, in a similar capillary storage scheme in the RePlay system we did not observe such mixing (28). To experimentally investigate this question, we placed defined plugs of ACN/1% acetone and water in the capillary loop, stored them for 0 or 60 min and monitored them with a UV detector (Fig. 2A, EXPERIMENTAL PROCEDURES). This did not lead to detectable mixing (Fig. 2B), confirming that storage of pre-formed gradients in a capillary loop is suitable for our purposes.

Having established that an analyte-containing gradient can be formed easily and stored in a loop, the next challenge was to obtain high chromatographic resolution with the help of an analytical column. A common issue in pre-column setups is peak broadening because peptides eluting from the pre-column are not sufficiently retained on the analytical column. To solve this issue, and to take account of the relatively large elution volume from the Evotip, we designed a gradient offset strategy. Once the Evotip is sealed in-line with the solvent system, a gradient from pumps A and B subsequently elutes the peptides from the tip. Directly after the Evotip, a secondary gradient from pumps C and D modifies the composition of the initial gradient and thus, reduces the effective organic content (Fig. 3A, 3B). With the offset gradient, peptides eluting from the loop are shortly retained at the head of the column and thereby focused (Fig. 3C). After separating on the analytical column, this results in the highest possible peak capacity. Note that due to the pre-formed and offset gradient the analytes are effectively loaded on the column in a sequential manner. Consequently, only a few percent of total peptide load is on the column at any given time (for instance, with a loop of 30 μl, a maximum of 3% for a 12 cm, 75 μm i.d. column which has a bed volume of less than one 1 μl).

After generation of the gradient, the loop-valve switches the storage loop in-line with the high-pressure pump and the analytical column (Fig. 3A). The high-pressure pump then pushes the pre-formed and offset gradient with embedded, pre-separated peptides over the analytical column. The fact that almost all the system’s functionality is contained in the low-pressure sub-system (Fig. 1), should ensure long lifetime of the mechanical components, and opens for ultra-precise flow manipulation, at a low risk of critical leaks and malfunction.

To test the Evosep One separation scheme, we loaded a BSA digest on an Evotip and eluted it in a 21 min gradient from an 8 cm analytical column (100 μm i.d., 3 μm C18 beads). This resulted in low peak widths (4.8 s median FWHM) and corresponding column capacities. Multiple injections illustrate that the chromatograms are virtually superimposable (Fig. 3D). An interesting consequence of our design is that it almost eliminates the loading and washing steps that are otherwise necessary between injections. Instead, the washing step is also encoded in the loop composition, and all remaining procedures take less than 3 min. This brings the total analysis time (injection to injection) very close to actual gradient time (21 min + 3 min). (Note that the instrument further-
more allows a higher flowrate at the beginning of the gradient, which would further compress the time to appearance of the first peptides in the gradient. Compared with conventional designs, this dramatically increases throughput, especially for short gradients, while avoiding the complexity and reproducibility issues of double column designs (29).

Robustness Development and Stress Test—Having established the basic principles of operation, we constructed a breadboard model that incorporates all functional components. As far as possible, we chose industry leading standard components, such as the CTC Analytics auto sampler and Vici rotary valves, whereas other components were custom designed for our throughput and robustness requirements (EXPERIMENTAL PROCEDURES). Pump firmware development was done in house but for other software development, we used the Chronos environment, an industry standard and widely used platform, with a view to integrate our instrument with the different MS manufacturers.

To optimize operation and optimize robustness, we injected 1 μg of a tryptic HeLa cell digest over 2000 times in a consecutive manner. We logged all issues over time and stopped the test only to optimize hardware or software components. In total, 35% of the measurements within the first 250 samples suffered from sample loss due to an imperfect seal of the autosampler needle and the tip. In a first step, we optimized the needle, which resulted in an immediate reduction of errors. After changing the seal between the tip and the entrance of the flow path as well, these issues were eliminated (Figs. 3A, 4A). From injection 513 on, all instrument related issues appeared to be resolved. We then mounted a new column to test the “partial elution” concept (as described in EXPERIMENTAL PROCEDURES) in subsequent injections. Over these 1500 samples the total ion current remained unchanged until the end of the experiment (Fig. 4B). A few LC-MS runs were blank, but this turned out to be due to incorrect manual loading of the corresponding Evotips.

We also recorded the pressure profiles for all runs. Validating the partial elution concept, there was only a very slight increase in backpressure, indicating that the column had remained free of deposits and as further evidence of the effect,
the TICs of runs 1 and 1500 were indeed highly similar and showing no decay in separation performance of the column. Pressure profiles of adjacent runs were virtually indistinguishable (Fig. 4C).

The Evosep One was intended and constructed for high throughput applications, with a focus on clinical analysis. Blood plasma is the most widely analyzed clinical matrix, with millions of samples drawn daily. Yet it is difficult to analyze plasma robustly by nano-LC/MS, mainly because of the large number of non-protein blood components. To demonstrate clinical applicability of the system, we employed our automated sample preparation pipeline—termed Plasma Proteome Profiling (Geyer et al. 2016a). Plasma samples were prepared and loaded on the Evotips in a 96 well format, using a robotic platform. The total measurement time for the 96 samples on the Evosep One was less than 2 days, corresponding to a throughput of 60 samples per day. Reproducibility over all 96 independent, parallel sample preparations and injections of the same original plasma was excellent (median Pearson correlation coefficient of 0.98) over all runs (Fig. 5B). For clinical decision making based on the concentration of biomarkers, it is crucial to ensure low carry-over from one analysis to the next. Therefore, we performed a cross contamination experiment with six alternating injections of plasma and blanks (Fig. 5B). The average carry-over was as low as 0.07% and 80% of this can be traced back to just 20 peptides (Fig. 5C).

**Fig. 4. Robustness evaluation.** A, Error frequency during the development phase of the system assessed by consecutive measurements of HeLa digests. B, The first and last base peak chromatogram of a HeLa digest in a series of 1500 measurements using a 22 min gradient. C, Pressure profiles over the gradient for the first and last three HeLa digests of the same experiment.

**Design of Methods for Desired Throughput and Depth**—Based on the principles explained above and the experiences from the robustness testing on the breadboard model, we then constructed the production unit. We devised a number of standard gradients and column combinations tailored to different applications, ranging from high throughput quality control of low complexity samples, through comprehensive proteomics using fractionation, to the in depth single run characterization of complex proteomes. The short gradients made possible by the Evosep system can be used for low complex samples and the somewhat longer ones for more complex samples.

Note that the design choices embodied in the Evosep One also imply certain limitations, at least in the current version. In common with previous efforts in “industrialized proteomics”, we chose to prioritize reliability, robustness and throughput over certain other parameters. The choice of relatively short and somewhat larger i.d. columns together with a flowrate of 1 μl/min, does not maximize sensitivity (however, this can easily be adjusted by the user). Likewise, sample introduction through the Evotip currently results in an elution volume optimized for gradients up to 44 min, whereas longer gradients would lead to broader peaks.
We characterized the chromatographic performance of each method using a synthetic peptide mix, spiked into the complex background of a HeLa digest. Parallel reaction monitoring targeting only the synthetic peptides extracted a detailed elution profile representative of typical proteomic measurements. From this data we calculated peak and retention time properties for the eluting peptides (Fig. 6A; supplemental Fig. S10–S14). Fig. 6B shows these data in tabular form for the optimized gradients and column dimensions for the standard use cases and sample types.

We first wished to demonstrate the possible throughput on low complexity samples. We digested the “UPS1 Proteomic Standard” (EXPERIMENTAL PROCEDURES) and used the 5.6 min gradient with the 2 μl/min flow on the 5 cm column (200 samples/day method). In a single day, this resulted in 200 data sets with very consistent protein coverage (Fig. 6C). The UPS1 should contain 48 different proteins but curiously four of them were never identified. As this standard is equimolar this is not an issue of dynamic range. Furthermore, the remaining 44 proteins were quantified essentially completely in all runs (average of 43.5 ± 1) (Fig. 6C). We conclude that the remaining proteins were likely missing from the kit. The high throughput for low complexity samples would be very interesting for single protein identification experiments in gel bands, for instance, or for contaminant analysis in recombinant protein expression in biotechnology. In many cases, it could also be enough for somewhat more complex mixtures such as those resulting from pull-down experiments.

Rapid Generation of In-depth Mammalian Cell Line Proteomes—Having shown the applicability of the system for low complexity samples in high throughput, we next investigated the rapid characterization of fractionated, high complexity proteomics samples. A fractionation step is very common in the analysis of cell line or tissue proteomes, but usually comes with the caveat of a drastic increase in measuring time as the number of fractions increases.

We built on a recently described strategy that combined extensive high pH reversed-phase peptide pre-separation in a first HPLC dimension without “concatenation” of the resulting fractions and relatively short gradients (4). Up to 70 such fractions were analyzed in gradients of 30 min, allowing for overall high peptide loading and high combined peak capacity and making optimal use of the high acquisition speed of state-of-the-art mass spectrometers (30). This resulted in a very deep coverage of cell line and tissue proteomes, on par with RNA-seq results (4). A bottleneck of the workflow was the low utilization of the mass spectrometer, due to the washing, equilibration and loading times of the HPLC, which are minimized with the Evosep system.

To characterize the efficiency for fractionated proteomes and to compare this to the Easy-nLC 1200 used as a standard in our laboratories as well as in the study described above, we performed an analysis of 46 HeLa fractions on both systems. Each of the fractions was divided and separately measured on the Easy-nLC and the Evosep One on the same MS instrument, recording total instrument time, the time utilized for gradients and the numbers of peptides and proteins identified. The Easy-nLC 1200 was run with our previously optimized 15 min gradients, whereas we used the 21 min gradient of the 60 proteomes/day method for the Evosep One.

As expected because of the short overhead time between runs, the Evosep One was significantly more efficient in terms of utilization of the mass spectrometer. A full 88% of the total analysis time of 18.4 h was spent on data acquisition (Fig. 7A). In contrast, the Easy-nLC 1200 occupied the mass spectrometer for 28.3 h, but only 14.6 h (52%) were productively used. This difference did not come at the expense of the numbers of identified peptides and proteins identified. The Easy-nLC 1200 was run with our previously optimized 15 min gradients, whereas we used the 21 min gradient of the 60 proteomes/day method for the Evosep One.

As expected because of the short overhead time between runs, the Evosep One was significantly more efficient in terms of utilization of the mass spectrometer. A full 88% of the total analysis time of 18.4 h was spent on data acquisition (Fig. 7A). In contrast, the Easy-nLC 1200 occupied the mass spectrometer for 28.3 h, but only 14.6 h (52%) were productively used. This difference did not come at the expense of the numbers of identified peptides and proteins, which was very comparable with 132,850 peptides (9918 proteins) and 130,450 peptides (9603 proteins) for the Evosep One and the Easy-nLC 1200, respectively. A detailed view of peptides identified in each
fraction separately or cumulatively, showed that they are very similar (Fig. 7B, 7C). This confirms our conclusion that the design principle of the Evosep One resulted in saving substantial measurement time (35% in this case), at undiminished performance. For longer gradients, the proportional time savings would be lower, however, given the high price of modern mass spectrometers, they would still be economically attractive. The above experiments show that the Evosep is well suited for the in-depth characterization of proteomes via the rapid analysis of the high pH or other fractions that are commonly used in proteomics. While we employed label-free quantitation here, the results should equally apply to isobaric labeling strategies. We also note that an average of 2700 proteins were identified in these fractions. There are several proteomics strategies that produce many fractions, such as thermal shift assays (31) or organellar proteomics (32), and our approach opens up for strategies to rapidly and robustly measure these.

**Single Shot, High Throughput HeLa Proteomes Using DIA**—The experiments described so far used data dependent ac-
quisition (DDA). However, data independent acquisition (DIA) is becoming increasingly popular and competitive (7). In our hands, we have found DIA to perform particularly well with relatively short gradients on fast and high resolution Orbitrap analyzers (5). The Evosep One with its fast turn-around between runs appeared to be a good addition to this strategy and we were curious to see how deep the proteome could be covered with such a combination. For this purpose, we made use of the very extensive peptide library generated in our previous experiments of the 46 fractions of HeLa digests using the Spectronaut software with one percent FDR at both precursor and protein levels.

Especially in short gradients, there is a trade-off between the number of peptide identifications and the quantification accuracy because of the finite time for a DIA cycle. To investigate this, we designed a faster (2 s cycle time, 15k MS/MS resolution) and a slower scanning method (4 s cycle time, 30k MS/MS resolution) as visualized in Fig. 8A. Given the short 21 min gradients (60 samples per day) the proteome coverage was very high for both methods with more than 5000 quantified proteins from more than 40,000 matched peptides. This equates to 250 unique proteins per gradient minute throughout the gradient. As expected, the slower method was somewhat superior in terms of identifications with a higher number of precursors (88,133 versus 81,007), peptide identifications (46,570 versus 40,642) and protein groups (5446 versus 5055) (Fig. 8B). For the fast and the slow method, the overlap of proteins between replicates was 81% and 85% with 4491 and 4904 proteins found in all five measurements, respectively (supplemental Fig. S15A). The faster method performed better with regard to protein quantification with 3286 proteins with a CV less than 20% in the slower versus 2724 in the faster method, respectively (Fig. 8C; supplemental Fig. S15B). For the top 70% of the proteome by abundance, data completeness was close to 100% (supplemental Fig. S15C). These results indicate that the short gradients enabled by

**Fig. 7. Rapid generation of mammalian cell line proteomes.** A, Table for the comparison of the Evosep One with the Easy-nLC 1200, including total measurement time, gradient time and the numbers for identified proteins and peptides. B, Numbers of identified peptides per fraction over the 46 high pH reversed-phase fractions for both LC systems. C, Cumulative numbers of unique peptides across the fractions.

**Fig. 8. Rapid generation of mammalian cell line proteomes.** A, Two scan modes for the acquisition of DIA data were devised and tested. B, Average number of precursors, identified peptides and protein groups for five HeLa measurements with 21 min gradients on the Evosep One. C, Number of proteins quantified with a coefficient of variation (CV) below 20 and 10%.
the Evosep One can very efficiently be combined with DIA for high-throughput and in-depth acquisition of proteomic data.

CONCLUSION

Despite the great technological advances in high sensitivity nano-flow MS-based proteomics, the robustness and throughput have been weak links even in state of the art MS-based proteomic workflows. This has led to a move toward microflow systems—especially with a view toward clinical applications—however, at the cost of sensitivity (33). Here, we have introduced an entirely novel concept based on the pre-formation of gradients at relatively high-flow and low-pressure. This pre-stored gradient already has the analytes embedded and is moved across a high-resolution column by a single, high-pressure pump. Based on these principles, we first designed a breadboard system that was progressively developed into a commercial HPLC system - the Evosep One. We established that pre-storing of the gradient, followed by “re-focusing” of the peaks at the head of the analytical column, assures full chromatographic peak capacity of the overall system. Together with the Evotip as a disposable sample clean up cartridge, the system is designed for sensitivity, throughput, and robustness - tailor made for large clinical studies. To test this, we performed thousands of runs with cell lysates as well as complex clinical samples such as blood plasma. We found that the decoupling of gradient formation with a low-pressure system and the high-pressure peptide separation ensured stable and uninterrupted operation without instrument related issues or deterioration in chromatographic performance. As expected from its design, the Evosep One proved to have minimal or absent cross contamination and very high consistency of label-free quantitation results across injections.

The time required for the formation of the pre-stored gradient, including the washing step, happens within 2–3 min, reducing the idle time of the mass spectrometer between injections. This opens up for the rapid analysis of samples of medium complexity, as we demonstrated with the measurement of 200 standard mixtures (UPS1) in a single day. The short gradients on the Evosep One are especially attractive in combination with time-of-flight (TOF) instruments because of their very high scanning speed. This was recently demonstrated by the identification of more than 1000 HeLa proteins in only 5.6 min (200 samples/day method) (34). Deep proteomes are typically achieved after extensive fractionation. In this context, the fast turn-around of the Evosep One ensures very high utilization of the MS instrumentation as we show by the analysis of 46 HeLa fractions in 18 h. Finally, we used a state-of-the-art data independent workflow that enabled a remarkable proteome depth of 5200 proteins in only 21 min (60 samples/day method). With ongoing developments on the mass spectrometric side, the proteome coverage is likely to improve further.

The minimal run-to-run times make even very short gradients efficient and attractive, opening up for high-throughput proteomics in areas like screening of host-cell proteins in pharma research, protein interaction studies and in particular clinical proteomics. We further imagine applications in top-down proteomics and in small molecule analysis, in particular metabolomes.

Acknowledgments — We thank all members of the department of Proteomics and Signal Transduction at the Max Planck Institute of Biochemistry in Martinsried for help and discussions, and Gaby Sowa for technical assistance.

DATA AND MATERIAL AVAILABILITY

The MS-based proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository and are available via ProteomeXchange with the identifier PXD010393. Tables containing all identified proteins are available with accession number, sequence coverage, number of identified peptides and quantitative values (Supplemental Tables S1–6).

* This work was partially supported by the Max Planck Society for the Advancement of Science, the European Union’s Horizon 2020 research and innovation program (grant agreement no. 686547; MSmed project) and by the Novo Nordisk Foundation (grant NNF14C0001).** This article contains supplemental Figures and Tables. The authors state that they have potential conflicts of interest regarding this work: NB, OH, LF, OV, are employees of Evosep and MM is an indirect investor in Evosep.

** To whom correspondence should be addressed: Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry Martinsried, Germany. E-mail: mmann@biochem.mpg.de.

These authors contributed equally.


REFERENCES


Molecular & Cellular Proteomics 17.11